Volume 11, Number 2—February 2005
Perspective
Managing Febrile Respiratory Illnesses during Hypothetical SARS Outbreaks
Kamran Khan*
, Peter Muennig†, Michael Gardam‡, and Joshua Graff Zivin†
, Peter Muennig†, Michael Gardam‡, and Joshua Graff Zivin†
Table 3
Cost-effectiveness of strategies for managing FRIs of undetermined etiology*
| Available public health strategies | Monthly total |
Incremental cost-effectiveness (cost per QALY gained) | |
|---|---|---|---|
| Costs ($ billion)† | QALY gained | ||
| Home isolation | 2.13 | 0 | – |
| Influenza testing |
2.14 |
5,286 |
$1,702 |
| Home isolation | 2.13 | 0 | – |
| Influenza testing | 2.14 | 5,286 | Dominated |
| Multiplex RT-PCR testing‡ |
2.05 |
8,474 |
Savings |
| Home isolation | 2.13 | 0 | – |
| SARS + influenza testing | 2.19 | 5,280 | Dominated |
| Influenza testing | 2.14 | 5,286 | Dominated |
| SARS + multiplex RT-PCR testing‡ | 2.14 | 8,429 | Dominated |
| Multiplex RT-PCR testing‡ | 2.05 | 8,474 | Savings |
*FRI, febrile respiratory illness; QALY, quality-adjusted life-year; RT-PCR, reverse transcription–polymerase chain reaction; –, reference category.
†Shown in 2004 U.S. dollars rounded to the nearest 10 million.
‡Multiplex RT-PCR testing to detect influenza viruses A and B, respiratory syncytial viruses A and B, parainfluenza viruses 1–3, human metapneumovirus, Bordetella pertussis, Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila, and L. micdadei.
Page created: April 27, 2011
Page updated: April 27, 2011
Page reviewed: April 27, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.